Pulmonary function in stereotactic body radiotherapy with helical tomotherapy for primary and metastatic lung lesions
- 1 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in La radiologia medica
- Vol. 126 (1), 163-169
- https://doi.org/10.1007/s11547-020-01223-w
Abstract
Aims This retrospective study reports outcomes after stereotactic body radiation therapy (SBRT) as delivered by helical tomotherapy (HT) for lung lesions. It promotes a dose escalation program. Methods Histological and/or radiological findings and/or case histories identified 41 primary and 15 metastatic lesions. Thirty patients received 40 Gy in 5 fractions (BED 72 Gy(10Gy)) and 26 50 Gy in 5 fractions (BED 100Gy(10Gy)). Primary end point was lung toxicity. Secondary end points were respiratory function, local control and local progression-free survival. Results Acute toxicity developed in 18/56 patients and late toxicity in 8/54. Median FEV-1 variations versus baseline were - 0.5% (range - 16 to + 43%) at 6 months and - 4.00% (range - 42 to + 18%) at 24 months. Median DLCO variations versus baseline were - 1% (range - 38 to + 36%) at 6 months and - 12.2% (range - 48 to + 11%) at 24 months. At 6 months, a significant positive correlation emerged between FEV-1 change and KPS (p = 0.047). At 24 months, a significant negative correlation emerged between FEV-1 change and the ipsilateral lung V5 (p = 0.006). A low baseline DLCO correlated with more marked DLCO worsening at 6 months (p = 0.012). At 24 months, DLCO worsening correlated significantly with the median contralateral lung dose (p = 0.003). At the last checkup, 23 patients were in complete remission, 16 were in partial remission, 5 had stable disease, and 7 were in relapse. Median follow-up was 12 months (range 5-56). Conclusions In patients with lung disease, SBRT, as delivered by HT, was well tolerated and provided good local control.This publication has 33 references indexed in Scilit:
- Significance of low-dose radiation distribution in development of radiation pneumonitis after helical-tomotherapy-based hypofractionated radiotherapy for pulmonary metastasesJournal of Radiation Research, 2013
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2012
- Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using TomotherapyRadiation Oncology, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable PatientsJournal of Thoracic Oncology, 2009
- Radiotherapy of lung cancer: Technology meets biology meets multidisciplinarityRadiotherapy and Oncology, 2009
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung MetastasesJournal of Clinical Oncology, 2009
- Baseline Pulmonary Function as a Predictor for Survival and Decline in Pulmonary Function Over Time in Patients Undergoing Stereotactic Body Radiotherapy for the Treatment of Stage I Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology*Biology*Physics, 2008
- A motion phantom study on helical tomotherapy: the dosimetric impacts of delivery technique and motionPhysics in Medicine & Biology, 2006
- Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: A noninvasive treatment approach in medically inoperable patientsInternational Journal of Radiation Oncology*Biology*Physics, 2004